Pathology of incipient pancreatic cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 4, 1999, Pages

  Hruban, R Hruban ^a,c   Wilentz, R E ^a   Goggins, M ^a   Offerhaus, G J A ^b   Yeo, C J ^a   Kern, S E ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Duct lesions; Hyperplasia; K ras; p16; p53; Pancreas; Pancreas cancer

Indexed keywords

PROTEIN P16; PROTEIN P53;

CONFERENCE PAPER; HISTOLOGY; HUMAN; MOLECULAR GENETICS; MORPHOLOGY; ONCOGENE; ONCOGENE K RAS; PANCREAS CANCER; PANCREAS ISLET CELL HYPERPLASIA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0032777035     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_4.S9     Document Type: Conference Paper

References (44)

1. Warshaw AL, Castillo CFD. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
2. Niederhuber JE, Brennan MF, Menck HR. The national cancer data base report on pancreatic cancer. Cancer 1995;76(9):1671-7.
3. Yeo CJ, Cameron JL, Lillemoe KD et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221:721-33.
4. Cubilla AL, Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 1976;36:2690-8.
5. Kozuka S, Sassa R, Taki T et al. Relation of pancreatic duct hyperplasia to carcinoma. Cancer 1979;43:1418-28.
6. Furukawa T, Chiba R, Kobari M et al. Varying grades of epithelial atypia in the pancreatic ducts of humans. Classification based on morphometry and multilvariate analysis and correlated with positive reactions of carcinoembryonic antigen. Arch Pathol Lab Med 1994;118:227-34.
7. Brat DJ, Lillemoe KD, Yeo CJ et al. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 1998;22(2):163-9.
8. Hruban RH, van Mansfeld ADM, Offerhaus GJA et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993;143(2):545-54.
9. Smit VTHBM, Boot AJM, Smits AMM et al. K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988;16:7773-82.
10. Mariyama M, Kishi K, Nakamura K et al. Frequency and types of point mutation at the 12th codon of the c-Ki-ras gene found in pancreatic cancers from Japanese patients. Jpn J Cancer Res 1989;80:622-6.
11. Nagata Y, Abe M, Motoshima K et al. Frequent glycine-to-aspartic acid mutations at codon 12 of c-Ki-ras gene in human pancreatic cancer in Japanese. Jpn J Cancer Res 1990;81:135-40.
12. Tada M, Yokosuka O, Omata M et al. Analysis of ras gene mutations in biliary and pancreatic tumors by polymerase chain reaction and direct sequencing. Cancer 1990;66:930-5.
13. Motojima K, Urano T, Nagata Y et al. Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. Ann Surg 1993;217:138-43.
14. Pellegata NS, Sessa F, Renault B et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994;54:1556-60.
15. Caldas C, Hahn SA, Hruban RH et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-73.
16. DiGiuseppe JA, Hruban RH, Offerhaus GJA et al. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol 1994;144:889-95.
17. Yanagisawa A, Ohtake K, Ohashi K et al. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 1993;53:953-6.
18. Tada M, Omata M, Kawai S et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993;53:2472-4.
19. Berthélemy P, Bouisson M, Escourrou J et al. Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Ann Intern Med 1995;123:188-91.
20. Sugio K, Molberg K, Albores-Saavedra J et al. K-ras mutations and allelic loss at 5q and 18q in the development of human pancreatic cancers. Int J Pancreatol 1997;21:205-17.
21. Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997;57:2140-3.
22. Tada M, Ohashi M, Shiratori Y et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterol 1996;110:227-31.
23. Cerny WL, Mangold KA, Scarpelli DG. K-ras mutation is an early event in pancreatic duct carcinogenesis in the syrian golden hamster. Cancer Res 1992;52:4507-13.
24. Seymour A, Hruban RH, Redston MS et al. Allelotype of pancreatic adenocarcinoma. Cancer Res 1994;54:2761-4.
25. Hahn SA, Seymour AB, Hoque ATMS et al. Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 1995;55:4670-5.
26. Hu YX, Watanabe H, Ohtsubo K et al. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin Cancer Res 1997;3:1473-7.
27. Huang L, Goodrow TL, Zhang S et al. Deletion and mutation analyses of the P16/MTS-1 tumor-suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res 1996;56:1137-41.
28. Caldas C, Hahn SA, da Costa LT et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
29. Bartsch D, Shevlin DW, Callery MP et al. Reduced survival in patients with ductal pancreatic adenocarcinonia associated with CDKN2 mutation. J Natl Cancer Inst 1996;88(10):680-2.
30. Naumann M, Savitskaia N, Eilert C et al. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterol 1996;110:1215-24.
31. Bartsch D, Shevlin DW, Tuna WS et al. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes Chromosomes Cancer 1995;14:189-95.
32. Wilentz RE, Geradts J, Maynard R et al. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression.. [In Press] Cancer Res 1998
33. Redston MS, Caldas C, Seymour AB et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-33.
34. DiGiuseppe JA, Hruban RH, Goodman SN et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994;101:684-8.
35. Casey G, Yamanaka Y, Friess H et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993;69:151-60.
36. Scarpa A, Capelli P, Mukai K et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993;142:1534-43.
37. Weyrer K, Feichtinger H, Haun M et al. p53, ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas. Lab Invest 1996;74:279-89.
38. Sugano K, Nakashima Y, Yamaguchi K et al. Sensitive detection of loss of heterozygosity in the TP53 gene in pancreatic adenocarcinoma by fluorescence-based single strand conformation polymorphism analysis using blunt end DNA fragments. Genes Chromosomes Cancer 1996;15:157-64.
39. Lundin J, Nordling S, von Boguslawsky K et al. Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology 1996;53:104-11.
40. Rozenblum E, Schutte M, Goggins M et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-4.
41. Hameed M, Marrero AM, Conlon KC et al. Expression of p53 nucleophosphoprotein in in situ pancreatic ductal adenocarcinoma: An immunohistochemical analysis of 100 cases. [Abstract] Lab Invest 1994;70:132A
42. Goggins M, Schutte M, Lu J et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-4.
43. Ozcelik H, Schmocker B, DiNicola N et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 1997;16:17-8.
44. Goggins M, Hruban RH, Kern SE. Relationship of BRCA2 germline mutation and pancreatic cancer intra-ductal lesions. [Abstract] Fourth Annual SPORE Meeting 1997;4:30